Experimental lung cancer drug trial halted early
Disease control
Terminated
This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if the drug was safe and could shrink tumors. The trial was stopped early, and only 19 pe…
Phase: PHASE1, PHASE2 • Sponsor: Therapex Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC